Biotech Hangout
Biotech Hangout

Nov 13, 2026 · 1h 1m

Biotech launches expose the gap between forecasts and adoption

Episode 203 - November 13, 2026

The episode connects policy uncertainty and cautious markets with the operational barriers that determine whether promising drugs reach patients.

3 key takeaways
  1. 1FDA predictability, China biotech, and possible MFN pricing could reshape development and commercialization strategy.
  2. 2Launch forecasts often miss access delays, physician habits, diagnostic gaps, and practice-level friction.
  3. 3PepGen’s early DM1 data show encouraging signals alongside small-sample and potential renal-safety uncertainties.

Don't miss

Kate Haviland explains why a well-resourced launch can still falter when diagnostic, workflow, access, and practice-level barriers block the final steps to treatment.

The brief

Paul Matteis, Kate Haviland, and the hosts assess cautious biotech markets, financing conditions, IPO selectivity, FDA leadership uncertainty, China biotech, and possible most-favored-nation pricing.

The panel argues that launch forecasts routinely understate access delays and physician behavior, while surveys and company guidance can reflect narrow samples or investor psychology.

Kate Haviland uses Blueprint’s Ayvakit experience to explain how claims, patient journeys, physician feedback, field teams, and commercial models are triangulated into launch expectations.

The discussion’s sharpest insight is that adoption can stall at the last mile: diagnostic delays, testing limits, electronic records, and practice economics obstruct specialized treatments.

Paul Matteis reviews PepGen’s early DM1 data, noting improved splicing and functional measures at a higher dose alongside a small sample and potential renal toxicity.

What was said on this episode

32 statements · 11 positive · 16 negative · 1 mixed · 4 neutral

  1. Josh Schimmeron Higher interest ratesNegative5:47

    Prolonged higher interest rates will likely hurt biotech companies.

    “higher rates again a little bit longer, they're probably not going to be great for biotechs”

    Listen at 5:47

  2. Josh Schimmeron Biotech sectorPositive6:39

    Biotech needs broader market stability to perform well.

    “we sort of need the market to be stable for biotech to do well”

    Listen at 6:39

  3. Josh Schimmeron AI market unwindNegative6:42

    A major AI unwind would likely impair biotech performance.

    “If we're going to continue to be seeing an unwind in AI in a major way, that's probably going to be too much of a seismic shift and waves in the market for biotech to react well to”

    Listen at 6:42

  4. Paul Matteison Biotech catalystsNegative7:11

    Investors find biotech catalysts difficult to monetize.

    “it's hard to get paid on catalysts”

    Listen at 7:11

  5. Paul Matteison Commercial biotech companies with pipelinesPositive7:21

    Commercial businesses with floor value and pipelines are trading relatively well.

    “companies that have. some sort of commercial business floor value semi-objective thing you can value plus any pipeline”

    Listen at 7:21

  6. Paul Matteison Biotech IPO marketNegative8:06

    Biotech IPO selection may become more selective going forward.

    “you kind of wonder now if things may be more selective going forward”

    Listen at 8:06

  7. Kate Havilandon Biotech reverse-merger marketPositive9:24

    The biotech reverse-merger market remains strong.

    “I think that market still looks pretty hot”

    Listen at 9:24

  8. Paul Matteison FDA drug regulationPositive13:43

    The FDA has recently restored advisory committees and pursued greater sponsor consistency.

    “bringing back ad comms, trying to make a concerted effort to be more consistent with sponsors”

    Listen at 13:43

  9. Paul Matteison FDA drug review processesPositive14:35

    FDA processes may become marginally faster under changed leadership.

    “perhaps we'll see things get like expedited on the margin”

    Listen at 14:35

  10. The FDA’s biggest need is additional staffing.

    “the biggest need at the FDA is just like getting more people”

    Listen at 14:44

  11. Paul Matteison DOGE FDA job cutsNegative14:53

    The DOGE approach to cutting FDA jobs was unsuccessful.

    “that like was not a success”

    Listen at 14:53

  12. Kate Havilandon FDA predictabilityPositive16:24

    Drug developers primarily need FDA predictability.

    “predictability is the number one thing we're looking for”

    Listen at 16:24

  13. Kate Havilandon FDA independencePositive16:45

    A science-driven independent FDA will be important for drug developers.

    “having a science-driven independent agency is going to be really important”

    Listen at 16:45

  14. Paul Matteison Drug launch pricingNegative19:21

    Many companies have launched drugs priced 20–50% above consensus expectations.

    “a lot of companies have been pricing at the outset of drug launches, you know, at levels that are 20 to 50 percent, sometimes above consensus price”

    Listen at 19:21

  15. Kate Havilandon MFN drug pricingNeutral21:38

    Companies expect some form of MFN drug-pricing debate to continue.

    “most of the people I speak to, the companies I'm involved in, are assuming that some form or fashion of this will be a continued dialogue”

    Listen at 21:38

  16. Kate Havilandon Ex-US rare-disease drug pricingNegative23:53

    Rare-disease drug prices in many ex-US markets were far below US prices.

    “the price was, in many of those markets, a very small fraction of the US price”

    Listen at 23:53

  17. Paul Matteison AmvuttraNegative27:11

    Alnylam’s Amvuttra launch has slowed below expectations.

    “The Almalum launch with Ambutra has kind of petered out”

    Listen at 27:11

  18. Paul Matteison Physician launch surveysNegative28:34

    Small physician samples may not represent broader prescribing behavior.

    “a point of view that might just not be broadly representative”

    Listen at 28:34

  19. Josh Schimmeron US drug market accessNegative29:25

    US market access is taking longer for new drugs.

    “access is just taking a lot longer in the US”

    Listen at 29:25

  20. Josh Schimmeron Drug adoptionNegative30:23

    Adoption takes longer for drugs treating non-life-threatening disorders.

    “these things really do take time, especially when they're not necessarily life-threatening disorders”

    Listen at 30:23

  21. Kate Havilandon Ayvakit market opportunityPositive39:03

    Blueprint viewed Ayvakit’s market as exceeding $1 billion.

    “it's a blockbuster market, it's going to be north of a billion”

    Listen at 39:03

  22. Kate Havilandon Physician drug adoptionNegative48:46

    Physician habit change and last-mile adoption strongly affect drug uptake.

    “physician habit change is really hard. And the last mile matters a lot.”

    Listen at 48:46

  23. Kate Havilandon RET inhibitor drugsMixed50:25

    RET inhibitors produce strong outcomes but underperformed market opportunity expectations.

    “the data on those drugs is amazing. Patients who are on them do extremely well. And they never lived up to what many very smart people thought the opportunity was going to be.”

    Listen at 50:25

  24. Kate Havilandon Community oncology drug adoptionNegative52:25

    Integrating targeted drugs into community oncology systems takes a long time.

    “it does take a long time”

    Listen at 52:25

  25. Kate Havilandon Oncology drug adoptionNeutral53:14

    Practice economics influence oncology drug adoption.

    “Practice economics matter”

    Listen at 53:14

  26. Kate Havilandon Oncology panel testingNegative53:52

    Many panel tests lack sufficient sensitivity for some mutations.

    “a lot of the panel testing, which should be a great solution, isn't sensitive enough”

    Listen at 53:52

  27. Kate Havilandon Oncology drug adoption frictionNegative55:19

    Diagnostic and adoption friction delays patient identification and commercial value capture.

    “any type of friction there is going to create delays in value capture or delays in patient identification”

    Listen at 55:19

  28. Kate Havilandon Community oncology treatmentNeutral56:18

    About 70% of oncology patients are treated in community settings.

    “70% of patients are treated in the community”

    Listen at 56:18

  29. Paul Matteison PepGen DM1 programPositive58:09

    PepGen’s higher dose improved muscle splicing by almost 50%.

    “they improve by almost 50 percent”

    Listen at 58:09

  30. Paul Matteison PepGen peptide conjugatesNegative58:19

    PepGen’s peptide-conjugate approach may carry renal toxicity risk.

    “these peptide conjugates also have this potential risk of renal tox”

    Listen at 58:19

  31. Paul Matteison ASO approach for DM1Positive59:08

    The ASO approach may be better suited to DM1 than alternatives.

    “we had believed this view that the ASO approach might be better”

    Listen at 59:08

  32. Paul Matteison PepGen DM1 dataPositive59:34

    PepGen’s data are positive for the company and modestly positive for the DM1 field.

    “it's another, it's great data for PepGen and maybe kind of an incremental positive data point for the space”

    Listen at 59:34

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Weekly email

State of the Pod, every Monday

The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.

Listen to the full episode and explore every guest, topic, and moment on PodLume.